Skip to main content
Fig. 4 | BMC Medicine

Fig. 4

From: Utility of comprehensive genomic profiling in directing treatment and improving patient outcomes in advanced non-small cell lung cancer

Fig. 4

Stratified analysis in patients carrying alterations with different actionability levels. A PFS and OS in patients carrying level 1–2 alterations who were treated with a matched therapy and a nonmatched therapy. B PFS and OS in patients carrying level 3–4 alterations who were treated with a matched therapy and a nonmatched therapy

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us